Menu
ncarol.com
  • Home
  • Business
  • Real Estate
  • Health
  • Non-profit
  • Beauty
  • Services
  • Arts
  • Education
ncarol.com

Lineus Medical's CEO Vance Clement joins the 2025 Association of Vascular Access Board of Directors
ncarol.com/10269488

Trending...
  • Uk Financial Ltd Featured In New York Business Now — 2019 Gold-Backed Bitcoin Prediction Now Becomes SEC Security Token Filing
  • MROVI Trailer Parts Launches Its Own Tire Brand: Introducing MROVI Tires and the New Didgori Trail Tread
  • The NoNickel Gift Guide: Stylish, Skin-Safe Gifts Under $50 (and One Worth the Splurge)
Lineus Medical CEO, Vance Clement AVA Logo Lineus Medical
FAYETTEVILLE, Ark. - ncarol.com -- Vance Clement, CEO of Lineus Medical, has been selected to join the Association of Vascular Access (AVA) Board of Directors as a Director at Large for a two-year term. AVA is an association of healthcare professionals whose mission is to advance the global practice of vascular access, through awareness, advocacy, and education to improve healthcare outcomes. Since 1985, they have worked to improve vascular access care and promote vascular access specialty. During Vance's time on the board, he will highlight the importance of vascular access care, provide support to local vascular access networks (VAN) across the nation, and grow AVA's membership.  When asked about being selected to join the board Vance said, "It is an honor to join the AVA Board of Directors.  I consider AVA to be the preeminent organization for anyone working in the vascular access space.  I look forward to helping AVA grow its membership."

Vance Clement has worked in the medical device industry for over 30 years. He is a frequent speaker at VAN chapter meetings across the country. He has served as the co-founder and CEO of Lineus Medical since 2015 and is passionate about improving IV care and advancing the science around IV care. Under his leadership, Lineus Medical brought the first break away device for medical lines, SafeBreak Vascular, to market.

More on ncarol.com
  • Canterbury Hotel Group Announces the Opening of the TownePlace Suites by Marriott Portland Airport
  • Heritage at South Brunswick's Resort-Style Amenities for Any Age and Every Lifestyle
  • T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
  • Record Revenues, Debt-Free Momentum & Shareholder Dividend Ignite Investor Attention Ahead of 2026–2027 Growth Targets: IQSTEL (N A S D A Q: IQST)
  • New YouTube Channel Pair Launches to Bring Entertainment Nostalgia Back to Life

SafeBreak Vascular is the only break-away device for IV lines proven to reduce IV complications.1 When a harmful force is placed on the line, SafeBreak intentionally separates to remove the damaging force and protect the patient's IV. When SafeBreak separates, valves on both ends of the device close preventing medicine spills from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money1.

About Lineus Medical

Lineus Medical is the developer of a break-away technology that is proven to reduce IV restarts and IV complications1. Our mission is to remove the pains associated with medical lines. More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn.

1.          Data on File

MKG 0287 Rev 00

Contact
Vance Clement
***@lineusmed.com


Source: Lineus Medical

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Kaufman Development Breaks Ground on Detroit Micro Data Center, Expanding Its National AI Platform
  • Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
  • $80M+ Backlog as Florida Statewide Contract, Federal Wins, and Strategic Alliance Fuel Next Phase of AI-Driven Cybersecurity Growth: Cycurion $CYCU
  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • Top10Christmas.co.uk Releases the UK Christmas Toy Trends 2025 Report
  • Talagat Business Academy Announces Joint Certificate Program With The University of Chicago Booth School of Business
  • LocaXion and Asseco CEIT Announce First-to-Market RTLS-Driven Digital Twin Platform for Healthcare, Manufacturing, and Logistics
  • Slotozilla Launches New Report on How AI Is Reshaping Careers and Society
  • High Rise: Path to Nowhere (2022) — A High-Stakes Thriller Filmed in Charlotte, North Carolina
  • OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
  • 15,000+ Fans Expected at the 2026 BIG HBCU Southern Classic Battle of the Bands in Charlotte
  • Explosive Growth in U.S. Cryptocurrency Cloud Mining Sets The Stage for New Platform Launch with Daily Rewards in a Transparent Revenue-Share Model
  • Qtex Cierra Ronda de $7 Millones para Estandarizar la Banca Transfronteriza en los Mercados Emergentes de Latinoamérica
  • America's Most Festive Garages Wanted for Garage.com's 2025 Holiday Contest
  • Railinc Launches RIGIS Routing+Mileage Application to Provide Accurate & Comprehensive Rail Routing
  • FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
  • BEC Technologies Expands MX-220 5G Industrial Router Series for Edge Connectivity
  • "Latino Leaders Speak: Personal Stories of Struggle and Triumph, Volume II" Documents the Truth About Latino Excellence and Impact on American Society
  • Broadway Smile Boutique Unveils Modern Website for Enhanced Patient Experience
  • Fenix Consulting Group Expands Orange County Office to Meet Growing Client Demand
_catLbl0 _catLbl1

Popular on ncarol.com

  • Liquidity Aggregation: US-Registered JHKXWL Integrates AI Analytics for Brazilian and Global Institutional Traders - 335
  • 5,000 Australians Call for Clarity: NaturismRE's Petition Reaches Major Milestone
  • NFL Midseason 2025: Who's for Real and Who's Faking It?
  • Wise Business Plans Launches Tailored Business Plan Writing Services for North Carolina Entrepreneur
  • Schemawriter.ai launches WordPress plugin as industry leaders confirm - schema markup is critical
  • PebblePad Announces Global Partnership with Inside Higher Ed and Times Higher Education
  • Dental Care Solutions Unveils New Website for Enhanced Patient Engagement
  • Putting Your Roses to Bed for Winter in the Deep South - A Gentleman's Guide to Fall Rose Care
  • POWER SOLUTIONS N.V. Partners with ENERGY33 LLC to Deliver a 40.5 MW Temporary Power Project for ECUACORRIENTE S.A. in Ecuador
  • Webinar Announcement: Reputational Risk Management in Internal Investigations: Controlling the Narrative Before, During, and After a Crisis

Similar on ncarol.com

  • T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
  • Record Revenues, Debt-Free Momentum & Shareholder Dividend Ignite Investor Attention Ahead of 2026–2027 Growth Targets: IQSTEL (N A S D A Q: IQST)
  • Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
  • $80M+ Backlog as Florida Statewide Contract, Federal Wins, and Strategic Alliance Fuel Next Phase of AI-Driven Cybersecurity Growth: Cycurion $CYCU
  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • LocaXion and Asseco CEIT Announce First-to-Market RTLS-Driven Digital Twin Platform for Healthcare, Manufacturing, and Logistics
  • Slotozilla Launches New Report on How AI Is Reshaping Careers and Society
  • Explosive Growth in U.S. Cryptocurrency Cloud Mining Sets The Stage for New Platform Launch with Daily Rewards in a Transparent Revenue-Share Model
  • Qtex Cierra Ronda de $7 Millones para Estandarizar la Banca Transfronteriza en los Mercados Emergentes de Latinoamérica
  • FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
Copyright © 2025 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute